Pureos Bioventures

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.

NovaGo Therapeutics AG is a biotech company based in Schlieren, Switzerland, focused on developing human antibody therapeutics for cerebral stroke and spinal cord injury. Founded in 2015, the company specializes in creating recombinant human monoclonal antibodies that target Nogo-A, a known inhibitor of nerve growth and regeneration. Its innovative therapies aim to stimulate nerve repair and enhance recovery in affected patients. NovaGo has established a strategic partnership with Neurimmune Holding AG, which provides access to a unique class of human-derived antibodies with significant therapeutic potential, developed using the Reverse Translational Medicine™ technology platform.